相互作用
Denosumab + Rozanolixizumab
重症度: 中等度
Denosumab and Rozanolixizumab: moderate interaction.
最終更新日
医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。
このページの臨床コンテンツは英語でのみ提供されています。
概要
Rozanolixizumab blocks the neonatal Fc receptor, reducing IgG recycling and shortening IgG half-life. Denosumab is an IgG2 antibody, so its exposure and antiresorptive effect could theoretically be reduced. Clinical data are lacking.
この相互作用をわかりやすく説明すると
Denosumab and Rozanolixizumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Denosumab belongs to Oncology; Rozanolixizumab belongs to Miscellaneous.
なぜ起こるのか
FcRn blockade accelerates IgG catabolism and may lower denosumab concentrations.
対処法
Monitor bone turnover markers and bone density for loss of effect. Consider alternative non-antibody antiresorptive therapy if denosumab is needed long term.
薬剤師に尋ねること
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+会員向け
ページ全体を見る
アカウントを作成してPro+トライアルを始めると、DenosumabとRozanolixizumabの臨床対応の詳細なアドバイス、追加の注記、エビデンスの詳細、処方全体を対象とした相互作用チェッカーを利用できます。
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
WebでPro+を7日間無料でお試し。カード登録不要。
Denosumabのその他の相互作用
Rozanolixizumabのその他の相互作用
よくある質問
Can I take Denosumab with Rozanolixizumab?
MediHelp rates the interaction as moderate. Denosumab and Rozanolixizumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Rozanolixizumab blocks the neonatal Fc receptor, reducing IgG recycling and shortening IgG half-life. Denosumab is an IgG2 antibody, so its exposure and antiresorptive effect could theoretically be reduced. Clinical data are lacking.
How serious is the interaction between Denosumab and Rozanolixizumab?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor bone turnover markers and bone density for loss of effect. Consider alternative non-antibody antiresorptive therapy if denosumab is needed long term.
What other medicines interact with Denosumab?
MediHelp also lists interactions of Denosumab with, for example, Abatacept, Adalimumab, Alefacept. The full list is on the Denosumab page.
完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで
MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。
